文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

ECPR患者治疗性低温、达标温度与低温持续时间与院内死亡率的关系:ELSO登记数据分析

Association of intentional cooling, achieved temperature and hypothermia duration with in-hospital mortality in patients treated with extracorporeal cardiopulmonary resuscitation: An analysis of the ELSO registry.
PubMed 文献 · Resuscitation · 2022-07-03
一句话结论ECPR患者中,治疗性低温整体未降低院内死亡率,但达标34-36°C并维持12-48小时与更低院内死亡率相关。

该研究为ELSO登记数据的回顾性分析,纳入2010-2019年接受ECPR的18-79岁患者1511例(总ECPR 4214例)。比较治疗性低温与无治疗性低温的院内90天内死亡率,并在完成治疗性低温的609例中比较达标温度(≤34°C、34-36°C、>36°C)和≤36°C持续时间(<12h、12-48h、≥48h)的死亡率。多变量Cox模型显示,治疗性低温与无治疗性低温的院内死亡率无显著差异(HR 1.06,95%CI 0.93-1.21;p=0.394);达标34-36°C较>36°C的调整HR显著更低(HR 0.73,95%CI 0.55-0.96;p=0.025);≤36°C维持12-48h较<12h的调整HR显著更低(HR 0.69,95%CI 0.53-0.90;p=0.005)。结论提示ECPR后治疗性低温整体未降低死亡率,但达标34-36°C并维持12-48h与更低院内死亡率相关。

要点

  • ECPR患者中,治疗性低温与无治疗性低温的院内90天内死亡率无显著差异(HR 1.06,95%CI 0.93-1.21;p=0.394)。
  • 完成治疗性低温的609例中,达标34-36°C较>36°C的院内死亡率调整HR显著更低(HR 0.73,95%CI 0.55-0.96;p=0.025)。
  • ≤36°C维持12-48h较<12h的院内死亡率调整HR显著更低(HR 0.69,95%CI 0.53-0.90;p=0.005)。
  • 研究为ELSO登记回顾性分析,纳入2010-2019年18-79岁ECPR患者,最终分析1511例(总ECPR 4214例)。
  • 主要终点为90天内院内死亡率,采用多变量Cox比例风险模型调整协变量。

适用人群与场景

  • 2010-2019年期间接受ECPR的18-79岁患者,来自ELSO登记数据库。
  • 最终分析纳入1511例,总ECPR患者4214例。
  • 完成治疗性低温的609例用于达标温度和持续时间分析。

诊断标准与关键阈值

  • 达标温度分组:≤34°C、34-36°C、>36°C。
  • ≤36°C持续时间分组:<12h、12-48h、≥48h。

处置流程与药物剂量

  • 比较治疗性低温与无治疗性低温;在完成治疗性低温者中比较达标温度和≤36°C持续时间。

研究设计与关键结果

  • 研究类型:ELSO登记数据库回顾性分析;样本量:总ECPR 4214例,最终分析1511例;人群:2010-2019年接受ECPR的18-79岁患者;主要终点:90天内院内死亡率。
  • 治疗性低温 vs 无治疗性低温:院内死亡率无显著差异(HR 1.06,95%CI 0.93-1.21;p=0.394)。
  • 完成治疗性低温的609例中,达标34-36°C vs >36°C:院内死亡率调整HR显著更低(HR 0.73,95%CI 0.55-0.96;p=0.025)。
  • 完成治疗性低温的609例中,≤36°C维持12-48h vs <12h:院内死亡率调整HR显著更低(HR 0.69,95%CI 0.53-0.90;p=0.005)。

证据类型、等级与局限

  • 证据类型:回顾性登记数据分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在ECPR患者中治疗性低温整体未降低院内死亡率,但达标34-36°C并维持12-48h与更低院内死亡率相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

AIM: To investigate whether intentional cooling, achieved temperature and hypothermia duration were associated with in-hospital death in patients treated with extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest.

METHODS: This is a retrospective analysis of the Extracorporeal Life Support Organization Registry. Patients 18-79 years of age who received ECPR between 2010 and 2019 were included. We compared outcomes for intentional cooling versus no intentional cooling. Then, among those who completed intentional cooling, we compared the outcomes between i) achieved temperature ≤ 34 °C, 34-36 °C, and > 36 °C, and ii) duration ≤ 36 °C for < 12 h, 12-48 h, and ≥ 48 h. The primary outcome was in-hospital mortality within 90 days. Cox proportional hazard models were generated with adjustment for covariates.

RESULTS: Among 4,214 ECPR patients, 1,511 patients were included in the final analysis. After multivariable adjustment, there was no significant difference in in-hospital mortality between patients with intentional cooling and no intentional cooling (hazard ratio [HR], 1.06 [95% CI 0.93-1.21]; p = 0.394). In the 609 patients who completed intentional cooling, temperature at 34-36 °C had a significantly lower adjusted HR for in-hospital mortality compared with > 36 °C (HR, 0.73 [0.55-0.96]; p = 0.025). Moreover, temperature ≤ 36 °C for 12-48 h had a significantly lower adjusted HR for in-hospital mortality compared with ≤ 36 °C for < 12 h (HR, 0.69 [0.53-0.90]; p = 0.005).

CONCLUSION: Intentional cooling was not associated with lower in-hospital mortality in ECPR patients. However, among patients with intentional cooling, achieving temperature of 34-36 °C for 12-48 h was associated with lower in-hospital mortality.

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Nakashima T, Ogata S, Noguchi T, et al. Association of intentional cooling, achieved temperature and hypothermia duration with in-hospital mortality in patients treated with extracorporeal cardiopulmonary resuscitation: An analysis of the ELSO registry. Resuscitation. 2022. PMID: 35788020. doi:10.1016/j.resuscitation.2022.06.022

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。